Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease

• Autori principali: C. J. J. Mulder (Autore), S. J. Van Den Hazel (Autore)
• Natura: Libro
• Pubblicazione: Hindawi Limited, 1998-01-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in maintaining a remission than lower dosages (1.5 g...